Zimmer Biomet stock (US98956P1021): institutional flows and analyst consensus in focus

Zimmer Biomet shares on the New York Stock Exchange continue to trade in a relatively narrow band, with the U.S. medical device group drawing attention on 06/01/2026 as new filings highlight shifting institutional positions and the current analyst consensus signals only moderate upside from recent price levels, according to MarketBeat data as of 05/29/2026.

The stock, listed in the United States under ticker ZBH, last closed at USD 82.46 on the NYSE on 05/29/2026, down 0.44% for the day and modestly below the 52-week midpoint, according to MarketBeat as of 05/29/2026. The shares have traded between USD 79.12 and USD 108.29 over the past 52 weeks, implying that the latest close leaves the stock closer to the lower end of its one-year trading corridor. In Germany, the stock is also available to retail investors via Tradegate in euros, providing an additional access point outside U.S. trading hours.

Fresh institutional ownership data underline that larger investors are actively adjusting their exposure. On 06/01/2026, MarketBeat reported that Geode Capital Management increased its holdings in Zimmer Biomet, while a separate filing showed that Thompson Siegel & Walmsley reduced its position by selling 76,365 shares, according to MarketBeat filing alert as of 06/01/2026 and MarketBeat institutional update as of 06/01/2026. These opposing moves emphasize that, while some institutions are trimming exposure, others are accumulating shares at current valuation levels.

The broader picture for the year-to-date shows that Zimmer Biomet has declined from USD 89.94 at the start of 2026 to around USD 82.46 by 05/29/2026, corresponding to a drop of roughly 8.3%, according to MarketBeat price data as of 05/29/2026. Over the same period, the company has maintained its dividend profile, with financial databases noting an annualized payout of around USD 0.96 per share and a yield close to 1% in 2025, even though the most recent ex-dividend date fell in June 2025, based on data compiled by StockAnalysis as of 05/29/2026.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

Zimmer Biomet: core business model

Zimmer Biomet focuses on musculoskeletal healthcare by designing and supplying joint replacement systems, trauma implants and related surgical technologies, with revenue primarily generated from sales of knee and hip implants, extremities solutions and associated services to hospitals and surgeons worldwide.

What banks and research houses say about Zimmer Biomet

Analyst coverage of Zimmer Biomet remains active, with data compiled by MarketBeat indicating that, as of 05/29/2026, the consensus rating across tracked research houses is "Hold" and the average price target stands at USD 102.70 for the NYSE-listed shares, according to MarketBeat as of 05/29/2026. This implies potential upside of around 24.5% versus the closing price of USD 82.46 on 05/29/2026, although individual targets and recommendations vary by bank and may be revised as new financial data or regulatory developments emerge.

In addition to the consensus compiled by MarketBeat, other financial research providers such as Morningstar have highlighted Zimmer Biomet in the context of value-oriented portfolios. Morningstar included the company in a list of U.S. value stocks trading materially below its internal fair value estimate of USD 130 per share as of 11/07/2025, underscoring that at that time the stock was viewed as undervalued relative to Morningstar's long-term assessment, according to Morningstar analysis as of 11/07/2025. While this valuation framework predates the most recent share-price moves and earnings releases, it still provides a reference point for the broader debate on how the market prices Zimmer Biomet's orthopedic and musculoskeletal franchise.

Conclusion

The latest trading levels of Zimmer Biomet on the NYSE, combined with newly reported institutional flows from firms such as Geode Capital Management and Thompson Siegel & Walmsley, frame the stock's current positioning in the U.S. market on 06/01/2026. Against this backdrop, the analyst consensus compiled by MarketBeat, alongside valuation perspectives from providers like Morningstar, offers investors a structured view of expectations on potential upside versus perceived risks around future operating performance. How the share price ultimately evolves will depend on upcoming earnings releases, regulatory developments and the broader demand environment for orthopedic and musculoskeletal treatments.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.